Stacey D. Seltzer

Ms. Seltzer joined Aisling in 2008 and currently serves as a Partner. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.

Ms. Seltzer serves as a director of Aimmune Therapeutics and Promentis Pharmaceuticals, and as a Board observer of AVROBIO and Prolacta Bioscience. Previously, she served as a director of Miramar Labs (acquired by Sientra), led Aisling’s investment in Synergy Pharmaceuticals and PreCision Dermatology (acquired by Valeant), and was a Board observer for Agile Therapeutics, Durata Therapeutics (acquired by Actavis) and ZELTIQ Aesthetics (acquired by Allergan). She was also closely involved in Aisling’s investments in Aclaris, Cytos, Dermira and PowerVision. Ms. Seltzer serves on the Life Science Council for Springboard Enterprises, the National Council for the Humane Society of the US, and the Investment Advisory Board of the Blavatnik Fund for Innovation at Yale.

Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her M.S. and B.S. from Yale University, awarded cum laude in Molecular Biophysics and Biochemistry.

Back to FinTech Speakers »

Subscribe to our newsletter
to stay informed:

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

CONTACT US

Potential Sponsor? Speaker? Questions? Get in touch.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.